SAGE Therapeutics (SAGE) Tops Q1 EPS by 70c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. WDC
2. DECK
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. TSCO
9. WCN
10. KNSL

Go back to SAGE Therapeutics (SAGE) Tops Q1 EPS by 70c, Revenues Miss

Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

May 7, 2020 4:01 PM EDT

Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications

April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M, with significant portion related to ZULRESSO commercial and G&A support

Progress continues in neurology and neuropsychiatry franchises with planned initiation of Phase 2 clinical trials of SAGE-324 in 1H and SAGE-718 in 2H, 2020

Mike Cloonan elevated to chief operating officer

Conference call today at 4:30... More